Nutritional Growth Solutions Ltd. announces a strategic leadership restructure to focus on the growth of its business in the North American market, with Mr. Stephen Turner, currently NGS President, North America, to transition to the role of CEO, effective 1 March 2023. Current NGS CEO and Managing Director, Ms. Liron Fendell, is to step down on the same date, remaining on the Board as a Non-Executive Director. Mr. Turner joined NGS in 2021, contributing over 20 years' industry experience having previously held senior roles with numerous multinational health and pharmaceutical companies.

He held the role VP of Sales at PharmaCare managing and controlling the sale functions across all lines of business for the company's brands including Sambucol, Promensil, Skin Doctors, Real Health, Real Health Superfoods and Kids Smart brands in North America. In his role of VP of Sales and Marketing at New York Stock Exchange listed Strides Pharma Science Ltd, an International pharmaceutical company specialising in development and manufacturing services, he was responsible for creating and building a new OTC Consumer Products division for North America as the company began branching out from generic prescription pharmaceuticals. Prior to his involvement with Strides, Mr. Turner served in various executive roles ranging from Chief Technology officer to CEO with SCOLR Technologies, a small public company that was previously traded on the American Stock Exchange and OTC Bulletin board stock exchanges.

During his tenure, he also gained significant experience in public companies and capital markets which involved liaising with investors, presenting to analysts and assisting in promoting the company to the investor and stockbroking community.